Revolution Medicines

Revolution Medicines

Yahoo Finance • 5 hours ago

Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?

Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone. Continue Reading... Full story

Yahoo Finance • 19 hours ago

Revolution Medicines reiterates $2.1B-$2.2B 2026 GAAP operating expense guidance following RASONQUE launch

Earnings Call Insights: Revolution Medicines (RVMD) Q3 2026 MANAGEMENT VIEW * "The third quarter marked a transformational period for Revolution Medicines" as the company said "the FDA approved RASONQUE" on August 26 and it "immediatel... Full story

Yahoo Finance • 21 hours ago

Revolution Medicines rises on Q3 beats; maintains 2026 guidance

[Q3 third annual business quarter evaluation blue large letters on business chart data] cagkansayin * Revolution Medicines is ~~6% higher in after-hours trading Wednesday after posting Q3 financial results that beat on both lines. * T... Full story

Yahoo Finance • 13 days ago

Tango Therapeutics stock falls despite positive cancer trial data

Investing.com -- Tango Therapeutics (NASDAQ:TNGX) shares fell 6% Friday following the company's presentation of Phase 1/2 study results for vopimetostat and daraxonrasib in pancreatic cancer, despite what the company characterized as promi... Full story

Yahoo Finance • 15 days ago

William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage

CHICAGO, October 21, 2026--(BUSINESS WIRE)--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansion of its biotech offering. Young join... Full story

Yahoo Finance • 16 days ago

RBC Capital names top healthcare stocks as sector upgraded to overweight

Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, po... Full story

Yahoo Finance • 20 days ago

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

[EU European Union Flags Side by Side Berlaymont Building Brussels Belgium] Mlenny/iStock via Getty Images An expert panel of the EU drug regulator endorsed six new medicines and five label expansions [https://www.ema.europa.eu/en/news/me... Full story

Yahoo Finance • 21 days ago

Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Revolution Medicines, Inc. Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and... Full story

Yahoo Finance • 22 days ago

Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug

Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment. Continue Reading... Full story

Yahoo Finance • 23 days ago

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity InsiderNews Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United Sta... Full story

Yahoo Finance • 30 days ago

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses. Continue Reading... Full story

Yahoo Finance • last month

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According... Full story

Yahoo Finance • last month

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

AIM ImmunoTech Inc. Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months... Full story

Yahoo Finance • 2 months ago

Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift

Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (ne... Full story

Yahoo Finance • 2 months ago

Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?

Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have receiv... Full story

Yahoo Finance • 2 months ago

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines, Inc. Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines... Full story

Yahoo Finance • 2 months ago

Patients with the deadliest cancer finally have something that works

For decades, a pancreatic cancer diagnosis came with almost no good options. The disease is usually caught late, spreads fast, and resists most treatments. Patients and their families were often left with months, not years. That grim pic... Full story

Yahoo Finance • 2 months ago

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer

Revolution Medicines RVMD announced that the FDA has approved its RAS inhibitor daraxonrasib for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug will be marketed under the brand name Rasonque.... Full story

Yahoo Finance • 2 months ago

Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution

NEW YORK, Aug. 26, 2026 /PRNewswire/ -- Bloomberg Indices announced the following changes to the Bloomberg 500 (B500) Index, effective prior to the open of trading on Thursday, September 10, 2026, to coincide with the September reconstitut... Full story

Yahoo Finance • 2 months ago

Sector Update: Healthcare Stocks Fall Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story